Freeport-McMoRan Inc. press release
LAWSUITS FILED AGAINST BMBL, GATO and CABA - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
NYSE - New York Stock Exchange · Copper · Gold · Molybdenum · United States
NEW YORK, NY / ACCESSWIRE / March 17, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Bumble Inc. (NASDAQ:BMBL)
CONTACT JAKUBOWITZ ABOUT BMBL: https://claimyourloss.com/securities/bumble-inc-loss-submission-form/?id=24838&from=1
This lawsuit is on behalf of all purchasers of the Class A common stock of Bumble directly in Bumble's secondary public stock offering which took place on or about September 10, 2021.
Lead Plaintiff Deadline:March 25, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Bumble's paying user growth trends had abruptly reversed in 3Q21 and the Company had actually lost tens of thousands of paying users during the quarter; (b) paying users had been more reluctant to sign up for the Bumble app during 3Q21 because of the recent price hike for paid services on the app; (c) a material number of paying users were leaving the Badoo app, a dating-focused social network, and/or could not make payments through the Badoo app due, in substantial part, to problems arising from the Company's transition of its payment platform; and (d) as a result of the foregoing, Bumble's business metrics and financial prospects were not as strong as the Registration Statement had represented.
Gatos Silver, Inc. (NYSE:GATO)
CONTACT JAKUBOWITZ ABOUT GATO: https://claimyourloss.com/securities/gatos-silver-inc-loss-submission-form/?id=24838&from=1
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Gatos: (a) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 28, 2020; and/or (b) securities between October 28, 2020 and January 25, 2022, inclusive.
Lead Plaintiff Deadline:April 25, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the technical report for Gatos's primary mine, the Cerro Los Gatos deposit, contained certain errors; (2) among other things, the mineral reserves had been overestimated by as much as 50%; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Cabaletta Bio, Inc. (NASDAQ:CABA)
CONTACT JAKUBOWITZ ABOUT CABA: https://claimyourloss.com/securities/cabaletta-bio-inc-loss-submission-form/?id=24838&from=1
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Lead Plaintiff Deadline: April 29, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: JAKUBOWITZ LAW 1140 Avenue of the Americas 9th Floor New York, New York 10036 T: (212) 867-4490 F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com: https://www.accesswire.com/693536/LAWSUITS-FILED-AGAINST-BMBL-GATO-and-CABA--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS